Lbp Am Sa Has $954,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lbp Am Sa lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 97.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,641 shares of the medical research company’s stock after selling 64,443 shares during the period. Lbp Am Sa’s holdings in Thermo Fisher Scientific were worth $954,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. FAS Wealth Partners Inc. raised its stake in shares of Thermo Fisher Scientific by 3.2% during the 4th quarter. FAS Wealth Partners Inc. now owns 772 shares of the medical research company’s stock valued at $410,000 after purchasing an additional 24 shares during the period. Stonegate Investment Group LLC raised its stake in shares of Thermo Fisher Scientific by 3.0% during the 4th quarter. Stonegate Investment Group LLC now owns 4,437 shares of the medical research company’s stock valued at $2,355,000 after purchasing an additional 130 shares during the period. Coastline Trust Co raised its stake in shares of Thermo Fisher Scientific by 12.1% during the 4th quarter. Coastline Trust Co now owns 13,860 shares of the medical research company’s stock valued at $7,357,000 after purchasing an additional 1,496 shares during the period. DAVENPORT & Co LLC grew its position in Thermo Fisher Scientific by 5.1% during the fourth quarter. DAVENPORT & Co LLC now owns 4,181 shares of the medical research company’s stock worth $2,219,000 after buying an additional 202 shares in the last quarter. Finally, Independence Bank of Kentucky grew its position in Thermo Fisher Scientific by 139.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,603 shares of the medical research company’s stock worth $1,382,000 after buying an additional 1,514 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.6 %

NYSE:TMO traded down $9.87 during trading hours on Friday, reaching $611.90. 683,619 shares of the company traded hands, compared to its average volume of 1,559,618. The business’s 50-day moving average price is $564.89 and its two-hundred day moving average price is $567.58. The stock has a market capitalization of $233.57 billion, a P/E ratio of 39.88, a P/E/G ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $622.30. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $5.15 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. TD Cowen boosted their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Evercore ISI cut their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, HSBC upped their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $618.94.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $602.09, for a total value of $3,793,167.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,548,375.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,084 shares of company stock valued at $19,767,092. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.